National Biotec Group, China's largest vaccines manufacturer, and the National Research Council of Canada signed a deal on 11 October to collaborate on vaccine development.
Under the agreement, the two sides will carry out joint studies on glycoconjugate vaccines and the bio-processing of vaccines as well as looking at ways to decrease production costs.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.